{"hands_on_practices": [{"introduction": "This practice will guide you through the application of the 2013 ACR/EULAR classification criteria, the cornerstone for diagnosing systemic sclerosis. Mastering this weighted scoring system is essential for accurately identifying patients, particularly those with early or atypical presentations, and is the first step in clinical management. This exercise will sharpen your ability to translate a patient's clinical and serological features into a definitive classification [@problem_id:4902483].", "problem": "A 52-year-old individual presents with features suggestive of systemic sclerosis, including sclerodactyly (skin thickening limited to the fingers and distal to the metacarpophalangeal joints), fingertip pitting scars (without active digital tip ulcers), telangiectasia on the face and hands, abnormal nailfold capillaries on capillaroscopy, Raynaud’s phenomenon, and a positive anti-centromere antibody. There is no skin thickening proximal to the metacarpophalangeal joints, no interstitial lung disease on high-resolution computed tomography, and no pulmonary arterial hypertension on right heart catheterization.\n\nUse the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for systemic sclerosis, which assign weighted points across domains, with the following foundational rules:\n- The classification score is the sum of weighted points across domains. Within a domain, only the highest applicable item is counted. The domains and weights are:\n  1. Finger skin thickening domain: puffy fingers $2$; sclerodactyly (skin thickening distal to the metacarpophalangeal joints) $4$; skin thickening of both hands extending proximal to the metacarpophalangeal joints $9$. If the proximal item ($9$) is present, this alone is sufficient for classification.\n  2. Fingertip lesions domain: digital tip ulcers $2$; fingertip pitting scars $3$.\n  3. Telangiectasia $2$.\n  4. Abnormal nailfold capillaries $2$.\n  5. Pulmonary arterial hypertension and/or interstitial lung disease $2$.\n  6. Raynaud’s phenomenon $3$.\n  7. Systemic sclerosis-related autoantibodies (anti-centromere, anti-topoisomerase I, or anti–RNA polymerase III) $3$.\n- A total classification score $\\geq 9$ classifies the patient as systemic sclerosis.\n\nCalculate the total classification score $S$ for this patient based on the given features and determine whether the score meets the classification threshold. Report your final answer as a row matrix $\\begin{pmatrix} S & I \\end{pmatrix}$, where $I = 1$ if the criteria are met and $I = 0$ otherwise. No rounding is required, and no units are to be included.", "solution": "The problem requires the calculation of a classification score for systemic sclerosis based on a set of clinical features and a specific scoring system, the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria. The final output should be a row matrix containing the total score and a binary indicator for whether the classification threshold is met.\n\n### Step 1: Extract Givens\n\nThe clinical features of the 52-year-old individual are:\n1.  Sclerodactyly (skin thickening limited to the fingers and distal to the metacarpophalangeal joints).\n2.  No skin thickening proximal to the metacarpophalangeal joints.\n3.  Fingertip pitting scars.\n4.  No active digital tip ulcers.\n5.  Telangiectasia on the face and hands.\n6.  Abnormal nailfold capillaries on capillaroscopy.\n7.  Raynaud’s phenomenon.\n8.  Positive anti-centromere antibody.\n9.  No interstitial lung disease on high-resolution computed tomography.\n10. No pulmonary arterial hypertension on right heart catheterization.\n\nThe 2013 ACR/EULAR classification criteria assign points as follows, with only the highest score within a domain being counted:\n- **Domain 1 (Finger skin thickening):** Puffy fingers ($2$ points); Sclerodactyly ($4$ points); Skin thickening proximal to metacarpophalangeal joints ($9$ points).\n- **Domain 2 (Fingertip lesions):** Digital tip ulcers ($2$ points); Fingertip pitting scars ($3$ points).\n- **Domain 3 (Telangiectasia):** $2$ points.\n- **Domain 4 (Abnormal nailfold capillaries):** $2$ points.\n- **Domain 5 (Pulmonary arterial hypertension and/or interstitial lung disease):** $2$ points.\n- **Domain 6 (Raynaud’s phenomenon):** $3$ points.\n- **Domain 7 (Systemic sclerosis-related autoantibodies):** $3$ points for anti-centromere, anti-topoisomerase I, or anti–RNA polymerase III.\n\nA total score $S \\geq 9$ classifies the patient as having systemic sclerosis. The classification indicator $I$ is $1$ if the criteria are met, and $0$ otherwise.\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem is scientifically grounded, well-posed, and objective. It is based on the established 2013 ACR/EULAR classification criteria, a standard tool in rheumatology. The problem provides all necessary data (patient features and scoring rules) to calculate a unique, deterministic score. The language is precise and free of ambiguity or subjective claims. The task is a formal application of a rule-based algorithm, which is a valid logical problem. Therefore, the problem is deemed valid and a solution can be derived.\n\n### Step 3: Calculation of the Total Classification Score\n\nLet $S$ be the total classification score. We will calculate the score by summing the points from each of the seven domains, adhering to the rule that only the highest-scoring item in each domain is counted.\n\n- **Domain 1: Finger skin thickening**\nThe patient has \"sclerodactyly (skin thickening limited to the fingers and distal to the metacarpophalangeal joints)\". The score for this item is $4$. The patient does not have skin thickening proximal to the metacarpophalangeal joints (which would score $9$), nor are \"puffy fingers\" mentioned as the primary finding. Thus, the score for this domain is $4$.\n\n- **Domain 2: Fingertip lesions**\nThe patient has \"fingertip pitting scars\". The score for this item is $3$. The patient does not have active digital tip ulcers (which would score $2$). Since $3 > 2$, the highest applicable score for this domain is $3$.\n\n- **Domain 3: Telangiectasia**\nThe patient has \"telangiectasia on the face and hands\". The score for this item is $2$.\n\n- **Domain 4: Abnormal nailfold capillaries**\nThe patient has \"abnormal nailfold capillaries on capillaroscopy\". The score for this item is $2$.\n\n- **Domain 5: Pulmonary arterial hypertension and/or interstitial lung disease**\nThe patient has \"no interstitial lung disease\" and \"no pulmonary arterial hypertension\". Therefore, no points are awarded for this domain. The score is $0$.\n\n- **Domain 6: Raynaud’s phenomenon**\nThe patient has \"Raynaud’s phenomenon\". The score for this item is $3$.\n\n- **Domain 7: Systemic sclerosis-related autoantibodies**\nThe patient has a \"positive anti-centromere antibody\". This is one of the specific SSc-related autoantibodies listed. The score for this item is $3$.\n\nThe total classification score $S$ is the sum of the points from each domain:\n$$S = (\\text{Score}_{Domain 1}) + (\\text{Score}_{Domain 2}) + (\\text{Score}_{Domain 3}) + (\\text{Score}_{Domain 4}) + (\\text{Score}_{Domain 5}) + (\\text\n{Score}_{Domain 6}) + (\\text{Score}_{Domain 7})$$\n$$S = 4 + 3 + 2 + 2 + 0 + 3 + 3$$\n$$S = 17$$\n\n### Step 4: Determine Classification Status\n\nThe threshold for classification is a total score $S \\geq 9$. The calculated score is $S = 17$.\nSince $17 \\geq 9$, the criteria for classifying the patient as having systemic sclerosis are met.\nTherefore, the indicator variable $I$ is equal to $1$.\n\nThe final answer is to be reported as a row matrix $\\begin{pmatrix} S & I \\end{pmatrix}$.\nSubstituting the calculated values, we get $\\begin{pmatrix} 17 & 1 \\end{pmatrix}$.", "answer": "$$\\boxed{\\begin{pmatrix} 17 & 1 \\end{pmatrix}}$$", "id": "4902483"}, {"introduction": "Once a diagnosis of systemic sclerosis is established, quantifying the extent of cutaneous involvement is critical for staging, prognostication, and monitoring treatment response. The modified Rodnan skin score ($mRSS$) is the gold-standard tool for this purpose. This exercise provides hands-on practice in calculating the $mRSS$ from regional assessments and interpreting the total score to categorize disease severity [@problem_id:4902503].", "problem": "A clinician is evaluating a patient with Systemic Sclerosis (SSc) and quantifies cutaneous involvement using the modified Rodnan skin score (mRSS). The mRSS is defined as the sum of palpation-based thickness grades across $17$ standardized body regions, each graded on an ordinal scale $0$ (normal), $1$ (mild), $2$ (moderate), or $3$ (severe). The $17$ regions are: face, anterior chest, abdomen, right and left upper arms, right and left forearms, right and left hands, right and left fingers, right and left thighs, right and left lower legs, and right and left feet. For this assessment, assume any region not explicitly listed has a score of $0$. The regional scores obtained are: face $1$, chest $2$, abdomen $1$, right upper arm $2$, left upper arm $2$, right lower arm $3$, left lower arm $3$, right hand $3$, left hand $3$, right thigh $1$, left thigh $1$, right lower leg $2$, left lower leg $2$, right foot $1$, and left foot $1$.\n\nUsing the formal definition of the mRSS as the sum of the $17$ regional scores, compute the total skin score $T$. Then, interpret disease severity using the following categorical mapping based on total skin score $T$: mild if $0 \\leq T \\leq 14$, moderate if $15 \\leq T \\leq 29$, and severe if $T \\geq 30$. Encode the severity category as a numeric code $S$ where $mild=1$, $moderate=2$, and $severe=3$.\n\nProvide your final answer as two values in a single row matrix, first the total mRSS $T$, second the severity code $S$. No rounding is required.", "solution": "The problem requires the computation of the modified Rodnan skin score (mRSS), denoted as $T$, for a patient with Systemic Sclerosis, and the subsequent determination of a disease severity code, $S$, based on the value of $T$.\n\nFirst, the problem is validated. All givens are extracted and assessed.\n- The definition of the mRSS is the sum of scores from $17$ specified body regions.\n- The scoring for each region is on an ordinal scale from $0$ to $3$.\n- A specific list of scores for $15$ out of the $17$ regions is provided.\n- A rule is given for unlisted regions: their score is $0$.\n- A categorical mapping from the total score $T$ to disease severity (mild, moderate, severe) is defined.\n- A numerical encoding for these severity categories is provided ($S=1, 2, 3$).\nThe problem is scientifically grounded in established rheumatological practice, well-posed with all necessary information, and objective. It contains no contradictions, ambiguities, or factual errors. Therefore, the problem is deemed valid and a solution can be derived.\n\nThe total score $T$ is the sum of the scores from the $17$ anatomical regions. Let $s_i$ be the score for the $i$-th region. Then, the total score is $T = \\sum_{i=1}^{17} s_i$.\n\nThe scores for the $17$ regions are as follows:\n- Face: $1$\n- Anterior Chest: $2$\n- Abdomen: $1$\n- Right Upper Arm: $2$\n- Left Upper Arm: $2$\n- Right Forearm: $3$\n- Left Forearm: $3$\n- Right Hand: $3$\n- Left Hand: $3$\n- Right Thigh: $1$\n- Left Thigh: $1$\n- Right Lower Leg: $2$\n- Left Lower Leg: $2$\n- Right Foot: $1$\n- Left Foot: $1$\n\nThe problem statement lists $15$ scores. The standard mRSS includes $17$ regions. The missing regions from the provided list are the right and left fingers. According to the problem statement, \"any region not explicitly listed has a score of $0$\". Therefore:\n- Right Fingers: $0$\n- Left Fingers: $0$\n\nNow, we can compute the total score $T$ by summing the scores of all $17$ regions:\n$$T = 1 (\\text{face}) + 2 (\\text{chest}) + 1 (\\text{abdomen}) + 2 (\\text{R upper arm}) + 2 (\\text{L upper arm}) + 3 (\\text{R forearm}) + 3 (\\text{L forearm}) + 3 (\\text{R hand}) + 3 (\\text{L hand}) + 0 (\\text{R fingers}) + 0 (\\text{L fingers}) + 1 (\\text{R thigh}) + 1 (\\text{L thigh}) + 2 (\\text{R lower leg}) + 2 (\\text{L lower leg}) + 1 (\\text{R foot}) + 1 (\\text{L foot})$$\n$$T = 1 + 2 + 1 + 2 + 2 + 3 + 3 + 3 + 3 + 0 + 0 + 1 + 1 + 2 + 2 + 1 + 1$$\nSumming these values:\n$$T = (1+2+1) + (2+2) + (3+3) + (3+3) + (0+0) + (1+1) + (2+2) + (1+1)$$\n$$T = 4 + 4 + 6 + 6 + 0 + 2 + 4 + 2$$\n$$T = 8 + 12 + 8$$\n$$T = 28$$\nThe total mRSS is $T=28$.\n\nNext, we determine the disease severity category based on $T$. The criteria are:\n- Mild: $0 \\leq T \\leq 14$\n- Moderate: $15 \\leq T \\leq 29$\n- Severe: $T \\geq 30$\n\nSince $T=28$, the condition $15 \\leq 28 \\leq 29$ is met. Therefore, the disease severity is classified as moderate.\n\nFinally, we encode this severity category into the numeric code $S$. The encoding rules are:\n- Mild $\\rightarrow S=1$\n- Moderate $\\rightarrow S=2$\n- Severe $\\rightarrow S=3$\n\nAs the severity is moderate, the corresponding code is $S=2$.\n\nThe problem asks for the final answer as two values in a single row matrix: the total mRSS $T$ and the severity code $S$.\nThe calculated values are $T=28$ and $S=2$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n28 & 2\n\\end{pmatrix}\n}\n$$", "id": "4902503"}, {"introduction": "Pulmonary complications are the leading cause of mortality in systemic sclerosis, making their early detection paramount. This exercise challenges you to interpret pulmonary function tests (PFTs), a vital non-invasive screening tool, to uncover evidence of both interstitial lung disease and pulmonary vascular disease. By analyzing the relationship between lung volumes ($FVC$) and gas transfer ($DLCO$), you will learn to identify patterns that warrant further investigation [@problem_id:4902472].", "problem": "A 54-year-old woman with limited cutaneous systemic sclerosis (lcSSc) presents with progressive exertional dyspnea over 6 months. She has no history of smoking, and her hemoglobin is $13\\,\\mathrm{g/dL}$. Pulmonary function testing (PFTs) demonstrates the following: pre-bronchodilator spirometry shows a preserved ratio of forced expiratory volume in 1 second to forced vital capacity ($FEV_1/FVC$) of $0.82$, and her forced vital capacity (FVC) is $55\\%$ of predicted. The diffusing capacity of the lung for carbon monoxide (DLCO), corrected for hemoglobin, is $30\\%$ of predicted. High-resolution computed tomography has not yet been performed. Using first principles of ventilatory mechanics and gas transfer, interpret these pulmonary function results and assess the severity of gas transfer impairment in the context of systemic sclerosis.\n\nWhich of the following interpretations is most accurate?\n\nA. Moderate restrictive ventilatory defect with severe impairment of gas transfer; the disproportionately reduced $DLCO$ relative to $FVC$ (i.e., $FVC\\%/DLCO\\% > 1.6$) raises concern for concurrent pulmonary arterial hypertension.\n\nB. Severe restrictive ventilatory defect with mild impairment of gas transfer, consistent with early interstitial lung disease.\n\nC. Obstructive ventilatory defect with severe gas transfer impairment due to emphysema.\n\nD. Normal lung volumes with moderate $DLCO$ reduction most likely due to anemia.\n\nE. Moderate restrictive ventilatory defect with severe gas transfer impairment entirely attributable to diffuse interstitial lung disease, with no concern for pulmonary vascular disease because $DLCO$ is expected to be lower than $FVC$ in interstitial lung disease.", "solution": "## PROBLEM VALIDATION\n\n### Step 1: Extract Givens\n- **Patient Demographics:** A 54-year-old woman.\n- **Diagnosis:** limited cutaneous systemic sclerosis (lcSSc).\n- **Clinical Presentation:** progressive exertional dyspnea over 6 months.\n- **Social History:** no history of smoking.\n- **Laboratory Data:** hemoglobin = $13\\,\\mathrm{g/dL}$.\n- **Pulmonary Function Testing (PFT) data:**\n    - Pre-bronchodilator spirometry ratio: $FEV_1/FVC = 0.82$.\n    - Forced vital capacity: $FVC = 55\\%$ of predicted.\n    - Diffusing capacity of the lung for carbon monoxide, corrected for hemoglobin: $DLCO = 30\\%$ of predicted.\n- **Imaging Status:** High-resolution computed tomography (HRCT) has not yet been performed.\n- **Task:** Interpret the PFT results and assess the severity of gas transfer impairment in the context of systemic sclerosis.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientific Grounding:** The problem is set in a clinical context (internal medicine/pulmonology) and uses standard, well-defined physiological measurements ($FVC$, $FEV_1$, $DLCO$) to evaluate a patient with a known disease (systemic sclerosis). The link between systemic sclerosis and pulmonary complications like interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) is a cornerstone of rheumatologic and pulmonary medicine. The presented values are clinically realistic. The problem is scientifically grounded.\n2.  **Well-Posed:** The problem provides a clear set of data and asks for an interpretation based on established pathophysiological principles. A unique and meaningful clinical interpretation can be derived from the given information. The problem is well-posed.\n3.  **Objective:** The data provided are objective measurements. The question asks for an interpretation based on these data, not a subjective opinion. The problem is objective.\n4.  **Completeness and Consistency:** The problem provides all necessary data for a first-pass interpretation of PFTs: lung volume ($FVC$), an index of airflow obstruction ($FEV_1/FVC$), and a measure of gas transfer ($DLCO$). It also provides relevant context (diagnosis, symptoms, smoking history, hemoglobin level). The hemoglobin value of $13\\,\\mathrm{g/dL}$ is normal for an adult female, ruling out significant anemia as a primary cause for a low $DLCO$. The fact that $DLCO$ is explicitly stated as \"corrected for hemoglobin\" is consistent with standard practice. The problem is self-contained and consistent.\n\n### Step 3: Verdict and Action\nThe problem statement is valid as it is scientifically grounded, well-posed, objective, and internally consistent. I will proceed with the solution.\n\n## SOLUTION DERIVATION\n\nThe interpretation of the pulmonary function tests will be performed by analyzing the ventilatory pattern and the gas transfer capacity, then synthesizing these findings within the clinical context of systemic sclerosis.\n\n**1. Analysis of Ventilatory Pattern (Spirometry)**\n\n- The ratio of forced expiratory volume in 1 second to forced vital capacity, $FEV_1/FVC$, is a primary determinant of the ventilatory pattern. A value less than the lower limit of normal (typically $0.70$) indicates an obstructive pattern. The patient's $FEV_1/FVC$ ratio is $0.82$, which is normal. This rules out a significant obstructive ventilatory defect.\n- The forced vital capacity ($FVC$) is a measure of the volume of air that can be forcibly exhaled after a maximal inspiration. It is an indicator of lung volume. The patient's $FVC$ is $55\\%$ of the predicted value. A reduced $FVC$ indicates a reduction in vital capacity.\n- The combination of a normal $FEV_1/FVC$ ratio and a reduced $FVC$ is the classic definition of a **restrictive ventilatory defect**. The severity of the restriction is graded based on the $FVC$ percentage of predicted:\n    - Mild: $FVC$ $65\\% - 79\\%$\n    - Moderate: $FVC$ $50\\% - 64\\%$\n    - Severe: $FVC$ $ 50\\%$\n- With an $FVC$ of $55\\%$ of predicted, this patient has a **moderate restrictive ventilatory defect**. This is consistent with processes that reduce lung compliance or volume, such as interstitial lung disease (ILD).\n\n**2. Analysis of Gas Transfer**\n\n- The diffusing capacity of the lung for carbon monoxide ($DLCO$) measures the integrity of the alveolar-capillary membrane for gas exchange. It reflects the surface area available for gas exchange and the thickness of the membrane.\n- The patient's $DLCO$, corrected for hemoglobin, is $30\\%$ of the predicted value. This indicates a profound defect in gas transfer. The severity of $DLCO$ impairment is typically graded as:\n    - Mild: $DLCO$ $60\\%$ - Lower Limit of Normal (~$75-80\\%$)\n    - Moderate: $DLCO$ $40\\% - 59\\%$\n    - Severe: $DLCO$ $ 40\\%$\n- With a $DLCO$ of $30\\%$, the patient has a **severe impairment of gas transfer**. This can be caused by alveolar-capillary membrane thickening/destruction (as in ILD) or by a loss of pulmonary capillary blood volume/surface area (as in pulmonary vascular disease like pulmonary arterial hypertension (PAH)).\n\n**3. Synthesis and Interpretation in the Context of Systemic Sclerosis (SSc)**\n\n- Systemic sclerosis is a known cause of both ILD (leading to restriction and low $DLCO$) and PAH (leading primarily to a low $DLCO$, often with preserved lung volumes initially).\n- The patient has both a moderate restrictive defect ($FVC=55\\%$) and a severe gas transfer defect ($DLCO=30\\%$). The restrictive defect is strong evidence for ILD.\n- A crucial step in evaluating SSc patients is to determine if the reduction in $DLCO$ is proportional to the reduction in lung volume ($FVC$) or if it is disproportionately low. A disproportionately low $DLCO$ suggests a concomitant pulmonary vascular component (i.e., PAH) in addition to the parenchymal disease (ILD).\n- A widely used clinical heuristic is the ratio of the percentages of predicted values: $FVC\\% / DLCO\\%$. A ratio greater than $1.4$ to $1.6$ is considered indicative of a high likelihood of PAH.\n- For this patient, the ratio is:\n$$ \\frac{FVC\\% \\text{ predicted}}{DLCO\\% \\text{ predicted}} = \\frac{55}{30} \\approx 1.83 $$\n- Since $1.83 > 1.6$, the $DLCO$ is disproportionately reduced relative to the $FVC$. This finding is highly concerning for the presence of concurrent pulmonary arterial hypertension on top of the interstitial lung disease suggested by the restrictive physiology.\n\n## OPTION-BY-OPTION ANALYSIS\n\n**A. Moderate restrictive ventilatory defect with severe impairment of gas transfer; the disproportionately reduced $DLCO$ relative to $FVC$ (i.e., $FVC\\%/DLCO\\% > 1.6$) raises concern for concurrent pulmonary arterial hypertension.**\n- This statement accurately classifies the $FVC=55\\%$ as a **moderate restrictive defect**.\n- It correctly classifies the $DLCO=30\\%$ as a **severe impairment of gas transfer**.\n- It correctly identifies that the $DLCO$ is disproportionately low relative to the $FVC$ and uses the correct threshold ($>1.6$) and calculation ($55/30 \\approx 1.83$).\n- It draws the correct clinical conclusion that this finding raises concern for concurrent pulmonary arterial hypertension.\n- **Verdict: Correct.**\n\n**B. Severe restrictive ventilatory defect with mild impairment of gas transfer, consistent with early interstitial lung disease.**\n- $FVC=55\\%$ represents a moderate, not severe, restrictive defect.\n- $DLCO=30\\%$ represents a severe, not mild, impairment of gas transfer.\n- The findings are not consistent with \"early\" disease.\n- **Verdict: Incorrect.**\n\n**C. Obstructive ventilatory defect with severe gas transfer impairment due to emphysema.**\n- The $FEV_1/FVC$ ratio of $0.82$ rules out an obstructive defect.\n- The patient has no history of smoking, a major risk factor for emphysema. Systemic sclerosis is the most relevant context.\n- **Verdict: Incorrect.**\n\n**D. Normal lung volumes with moderate $DLCO$ reduction most likely due to anemia.**\n- Lung volumes are not normal; the $FVC$ is moderately reduced at $55\\%$.\n- The $DLCO$ reduction is severe ($30\\%$), not moderate.\n- The patient's hemoglobin of $13\\,\\mathrm{g/dL}$ is normal, so anemia is not the cause. Furthermore, the $DLCO$ was already corrected for hemoglobin.\n- **Verdict: Incorrect.**\n\n**E. Moderate restrictive ventilatory defect with severe gas transfer impairment entirely attributable to diffuse interstitial lung disease, with no concern for pulmonary vascular disease because $DLCO$ is expected to be lower than $FVC$ in interstitial lung disease.**\n- This statement correctly identifies the moderate restrictive defect and severe gas transfer impairment.\n- However, the conclusion that this is \"entirely attributable to diffuse interstitial lung disease\" with \"no concern for pulmonary vascular disease\" is incorrect and clinically dangerous. While $DLCO\\%$ is often lower than $FVC\\%$ in ILD, the *magnitude* of the disproportion ($FVC\\%/DLCO\\% \\approx 1.83$) is a specific warning sign for coexisting PAH. To ignore this sign would be a significant clinical error.\n- **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "4902472"}]}